Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing the previous v3.6.3. This indicates a backend or tooling update rather than a change to the visible study details.SummaryDifference0.0%

- Check20 days agoChange DetectedThe Publications section, including the PubMed-listed article and the auto-fill note about PubMed entries, has been removed from the study page. This reduces visible references and attribution for the study without altering core trial details.SummaryDifference0.2%

- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedThe page's revision tag changed from v3.6.2 to v3.6.3, indicating an updated version of the page. This update does not modify the core study details or user-facing content beyond the version label.SummaryDifference0.0%

- Check42 days agoChange DetectedPage revision updated from v3.6.0 to v3.6.2, representing a newer version of the page's template or metadata. No substantive study details, eligibility criteria, or results appear to be changed.SummaryDifference0.0%

- Check49 days agoChange DetectedLinks and metadata for study documents were added, including PDF versions of the Statistical Analysis Plan and Study Protocol, along with notes on IPD plans and related MeSH terms. These updates provide researchers with direct access to the study's methodology and regulatory context.SummaryDifference63%

- Check56 days agoChange DetectedRevision: v3.6.0 was added. Several study documents and metadata (PDFs, protocols, IPD plans, collaborators) were removed from the study record.SummaryDifference18%

Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.